Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, et al. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3.”. Blood Cancer J. 2022;12:55.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, et al. Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022;97:1427–34.

Article  PubMed  CAS  Google Scholar 

Yoon JH, Kim HJ, Kim JW, Jeon YW, Shin SH, Lee SE, et al. Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation. Bone Marrow Transpl. 2014;49:1466–74.

Article  CAS  Google Scholar 

Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries R, Loken MR, et al. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in cbf acute myeloid leukemia. Clin Cancer Res. 2019;25:5038–48.

Article  PubMed  PubMed Central  Google Scholar 

Christen F, Hoyer K, Yoshida K, Hou HA, Waldhueter N, Heuser M, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019;133:1140–51.

Article  PubMed  CAS  Google Scholar 

Jahn N, Terzer T, Sträng E, Dolnik A, Cocciardi S, Panina E, et al. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Adv. 2020;4:6342–52.

Article  PubMed  PubMed Central  Google Scholar 

Lo MY, Tsai XCH, Lin CC, Tien FM, Kuo YY, Lee WH, et al. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. Am J Hematol. 2023;98:760–9.

Article  PubMed  CAS  Google Scholar 

Xu D, Yang Y, Yin Z, Tu S, Nie D, Li Y, et al. Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study. Blood Cancer J. 2023;13:168.

Article  PubMed  PubMed Central  Google Scholar 

Shang L, Chen X, Liu Y, Cai X, Shi Y, Shi L, et al. The immunophenotypic characteristics and flow cytometric scoring system of acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. Int J Lab Hematol. 2019;41:23–31.

Article  PubMed  Google Scholar 

van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265–81.e24.

Article  PubMed  PubMed Central  Google Scholar 

Valk PJM, Verhaak RGW, Beijen MA, Erpelinck CAJ, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl J Med. 2004;350:1617–28.

Article  PubMed  CAS  Google Scholar 

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

Article  PubMed Central  Google Scholar 

Mo XD, Wang Y, Zhang XH, Xu LP, Yan CH, Chen H, et al. Interferon-α is effective for treatment of minimal residual disease in patients with t(8;21) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: results of a prospective registry Study. Oncologist. 2018;23:1349–57.

Article  PubMed  PubMed Central  CAS  Google Scholar